Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to give their informed consent to participate.
- People aged 21 or older who have been newly diagnosed with IPF (a type of lung scarring disease) within the last 12 months by the enrolling centre.
- People diagnosed with a non-IPF interstitial lung disease (ILD) — a group of conditions that cause scarring or inflammation in the lungs — of any duration, including conditions such as iNSIP, unclassifiable IIPs, IPAF, Rheumatoid Arthritis-related ILD, Systemic Sclerosis-related ILD, Chronic Hypersensitivity Pneumonitis, Sarcoidosis, or asbestosis (confirm with trial site for the full list).
- For people with non-IPF ILD, the condition must show a specific pattern of lung scarring confirmed by a high-resolution CT scan of the chest and/or a lung tissue sample (biopsy).
- For people with non-IPF ILD, the disease must also have been getting worse over the last 24 months, shown by at least one of the following: a significant drop in lung capacity (FVC) of 10% or more; a smaller drop in lung capacity (5–10%) combined with worsening breathing symptoms; a smaller drop in lung capacity (5–10%) combined with more scarring visible on chest scans; a significant drop in the lungs' ability to transfer oxygen into the blood (DLCO) of 10% or more; or worsening breathing symptoms alongside increased scarring on chest scans, regardless of lung capacity changes.
Who may not be able to join:
- People who have had any cancer (other than certain skin cancers or early-stage prostate cancer) within the past 5 years, whether treated or not.
- People who are already on a waiting list for a lung transplant at the time of enrolment.
- People who are currently taking part in another interventional clinical trial at the time of enrolment.
- People who have previously been enrolled in this same registry (this applies specifically to the additional IPF group of 1,000 participants).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Scott Palmer, MD, Duke Clinical Research Institute, Duke University
Phone: 919-660-0890
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Data on natural history of IPF & non-IPF chronic fibrosing ILD; Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD; Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.; Blood samples for future research.; HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.